Immune cells linked to Epstein-Barr virus may play a role in multiple sclerosis

Notice: News releases are not subject to review by MedLink Neurology’s Editorial Board.

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus could contribute to multiple sclerosis, a chronic autoimmune disease that affects nearly one million Americans.

The study, published Feb. 5 in Nature Immunology, found that certain types of CD8+ “killer” T cells — immune cells that destroy damaged or infected cells — are more abundant in people with multiple sclerosis. Some of these killer T cells target Epstein-Barr virus, which suggests that the virus may trigger the damaging immune response seen in multiple sclerosis.

Scientists have known for several years that Epstein-Barr virus — a common virus carried by about 95% of adults — is present in virtually everyone who develops multiple sclerosis.

“Looking at these understudied CD8+ T cells connects a lot of different dots and gives us a new window on how Epstein-Barr virus is likely contributing to this disease,” said senior author Joe Sabatino, MD, PhD, an assistant professor of Neurology who is a member of the UCSF Weill Institute for Neurosciences.

Multiple sclerosis develops when the immune system mistakenly attacks the myelin that coats nerve fibers in the brain and spinal cord, leading to progressive neurological damage. Until now, most multiple sclerosis research has focused on CD4+ T cells, which coordinate immune responses but do not directly kill cells. CD4+ T cells are easier to study in animal models of multiple sclerosis than CD8+ killer T cells.

Sabatino’s team decided to examine the killer T cells directly in people. They analyzed blood and cerebrospinal fluid (CSF) from 13 patients with multiple sclerosis or early signs of the disease, as well as five people without multiple sclerosis.

The researchers looked at CD8+ T cells that recognized specific proteins in each of these fluids.

In the study, participants without multiple sclerosis, the cells that recognized these proteins were similarly abundant in the blood and CSF. But in the participants with multiple sclerosis, these cells were between 10 and 100 times more abundant in the CSF than in the blood. This huge difference indicated that something unusual must be happening in the central nervous system — and that the immune cells were responding to it.

The Epstein-Barr virus was also present in the CSF of most study participants, whether or not they had multiple sclerosis, and some of its genes were active. One of these genes was only active in people with multiple sclerosis, which suggests that it may be driving the overactive immune response characteristic of multiple sclerosis.

The findings are just the latest to implicate Epstein-Barr virus in autoimmune disease. Along with multiple sclerosis, the virus has been linked to lupus, rheumatoid arthritis, and long COVID.

Some multiple sclerosis researchers have already begun testing therapies that target Epstein-Barr virus.

“The big hope here is that if we can interfere with Epstein-Barr virus, we can have a big effect, not just on multiple sclerosis but on other disorders, and improve the quality of life for many, many people,” Sabatino said.

Source: News Release
University of California - San Francisco
February 5, 2026